Abu Dhabi Global Healthcare Week Partners with Digital Health New York to Boost Digital Health Ecosystem

By HEOR Staff Writer

October 8, 2023

Unifying Efforts for Digital Health Ecosystem Globally

Abu Dhabi Global Healthcare Week (ADGHW) has partnered with Digital Health New York (DHNY) to enhance the global digital health ecosystem. The Memorandum of Understanding (MoU), signed on October 4, 2023, aims to promote collaboration, innovation, long-term investment, and knowledge exchange in the digital health sector.

The two-year partnership will focus on developing research and innovation in digital health, enhancing credibility in science, and providing access to subject-matter experts through open dialogue.

Tackling Global Healthcare Challenges through Digital Tools

The partnership comes at a time when global healthcare demands require collaboration and access to digital tools. Both ADGHW and DHNY are committed to supporting ongoing research and development initiatives, particularly in genomics, preventative and predictive medicine.

H.E. Dr. Ahmed Alkhazraji, Executive Director, Strategy and Policy at the Department of Health – Abu Dhabi and Bunny Ellerin, Co-Founder & CEO, DHNY, signed the partnership. The collaboration aims to leverage both parties’ rich networks to access long-term investment and forge partnerships in the global digital health arena.

ADGHW and DHNY also emphasise the importance of scientific credibility in the healthcare industry and are joining forces in collaborative research studies and the creation of scientific literature.

Reference url

Recent Posts

Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
EMA’s mCombriax Vaccine Recommendation
EMA's mCombriax Vaccine Recommendation Ushers in Dual Protection Era The mCombriax vaccine recommendation from the European Medicines Agency (EMA) marks a milestone for individuals aged 50 and older. EMA has recomm...
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC

By HEOR Staff Writer

March 2, 2026

FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option HERNEXEOS lung cancer treatment (zongertinib tablets), developed by